Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Smruthi Organics Ltd
Your Vote -
Buy
50.00%
Hold
25.00%
Sell
25.00%
50.00%
4 users have voted
Option Chain
Analyzes market sentiment, predicts Smruthi Organics Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Smruthi Organics - Intimation Of Record Date For Payment Of Dividend
-
Smruthi Organics - Intimation Of Date Of Annual General Meeting Of The Company
-
Smruthi Organics - Record Date For Dividend
-
Smruthi Organics - Book Closure For The Purpose Of The 37Th Annual General Meeting And Payment Of Dividend
-
Smruthi Organics Q4 net profit down 52.02% at Rs 1.07 cr
-
Smruthi Organics - Corporate Action-Board approves Dividend
-
Smruthi Organics - Announcement under Regulation 30 (LODR)-Change in Management
-
Smruthi Organics - Audited Financial Results For The Quarter And Financial Year Ended 31St March 2026
-
Smruthi Organics - Board Meeting Outcome for Outcome Of Board Meeting Of The Company Held Today I.E 13Th May 2026
-
Smruthi Organics - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligat
-
Smruthi Organics - Clarification On Website Disclosures For BSE Query
-
Smruthi Organics has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026
-
Smruthi Organics - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Smruthi Organics - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Smruthi Organics - Intimation Under Regulation 30 Of SEBI (LODR) Regulations - Receipt Of CEP Certificate From EDQM
Key fundamentals
Evaluate the intrinsic value of Smruthi Organics Ltd stock
| Name | March-26 | March-25 | March-24 | March-23 | March-22 |
|---|---|---|---|---|---|
| Assets | 81.8796 | 88.4287 | 81.3221 | 73.8533 | 70.0387 |
| Liabilities | 81.8796 | 88.4287 | 81.3221 | 73.8533 | 70.0387 |
| Equity | 11.4463 | 11.4463 | 11.4463 | 11.4463 | 11.4462 |
| Gross Profit | 13.0365 | 12.1822 | 11.9557 | 9.7806 | 18.4283 |
| Net Profit | 3.4257 | 3.5629 | 3.5903 | 4.1309 | 10.3817 |
| Cash From Operating Activities | 22.2595 | 9.9762 | 4.4009 | 12.1051 | 1.91 |
| NPM(%) | 3.35 | 2.82 | 2.81 | 2.92 | 7.78 |
| Revenue | 101.9671 | 126.0079 | 127.6431 | 141.0409 | 133.3715 |
| Expenses | 88.9306 | 113.8257 | 115.6874 | 131.2603 | 114.9431 |
| ROE(%) | 4.74 | 4.93 | 4.97 | 5.72 | 14.37 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Smruthi Organics Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 704.30 | -2.42 | 0.00 | 70.48 | -26.19 | 0.71 |
| Lotus Eye Hospital and Institute Ltd | 108.05 | -1.05 | 3619.00 | 256.83 | 3.55 | 0.00 |
| Bharat Immunological and Biologicals Corporation Ltd | 17.50 | -1.30 | 0.00 | 533.27 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 770.75 | 1.41 | 0.00 | 242.20 | -363.15 | 0.00 |
Company Info
1995 -Smruthi Organics a bulk drug manufacturing company has decided to expand its product range by the introduction of Ciprofloxacin (antibiotic) and Ranitidine HCl. To part finance this project the company is entering the capital market on December 4th with a public issue of 18 88 550 lakh equity shares of Rs. 10 each at a premium of Rs. 5 per share. 2005 - The Company's Block No C and D being dedicated for exports and received 100% EOU status permission from the Development Commissioner, Seepz, Mumbai and started the activities. 2006 - The Company has created new facility i.e.; additional production plant viz. 'E' Block' at the Company's Factory No. Unit II Plot No A-27, MIDC, Chincholi, Solapur has commenced the commercial operation as an Export Oriented Unit. - The Board of Directors have recommended a dividend of 25% for the financial year. 2007 - The Company has been accredited the Current Good Manufacturing Practices - World Health Organization (cGMP - WHO) certificate from German Health Authorities (Landesamt fur Gesundheist and Soziales Berlin, Germany) for Active Pharmaceutical Ingredients (API) viz. Norfloxacin, Carbidopa and Metformin Hydrochloride for the European Union. 2009 - "Amlodipine Besilate (API)" has been granted Certificate of Suitability (COS) by European Directorate from the Quality of Medicines and Healthcare (EDQM). This recognition shall immensely help the Company to Enter EU Regulatory business in EU Countries. 2011 - Smruthi Orga - Manufacturing site U-II received USFDA approvals. - Recommendation of Dividend @ 25% on Equity Shares i.e. Rs. 2.50 per share. 2012 - The Board of Directors has recommended a dividend of 30% on Equity Shares of Rs. 10/- each for the year. 2021 -The Company has issued Bonus Shares in the Ratio of 2:1. 2023-The Company's Flagship API site has been successfully inspected by Ministry of Food and Drug Safety, Republic of South Korea leading to the registration of product in the Korean market.
1995 -Smruthi Organics a bulk drug manufacturing company has decided to expand its product range by the introduction of Ciprofloxacin (antibiotic) and Ranitidine HCl. To part finance this project the company is entering the capital market on December 4th with a public issue of 18 88 550 lakh equity shares of Rs. 10 each at a premium of Rs. 5 per share. 2005 - The Company's Block No C and D being dedicated for exports and received 100% EOU status permission from the Development Commissioner, Seepz, Mumbai and started the activities. 2006 - The Company has created new facility i.e.; additional production plant viz. 'E' Block' at the Company's Factory No. Unit II Plot No A-27, MIDC, Chincholi, Solapur has commenced the commercial operation as an Export Oriented Unit. - The Board of Directors have recommended a dividend of 25% for the financial year. 2007 - The Company has been accredited the Current Good Manufacturing Practices - World Health Organization (cGMP - WHO) certificate from German Health Authorities (Landesamt fur Gesundheist and Soziales Berlin, Germany) for Active Pharmaceutical Ingredients (API) viz. Norfloxacin, Carbidopa and Metformin Hydrochloride for the European Union. 2009 - "Amlodipine Besilate (API)" has been granted Certificate of Suitability (COS) by European Directorate from the Quality of Medicines and Healthcare (EDQM). This recognition shall immensely help the Company to Enter EU Regulatory business in EU Countries. 2011 - Smruthi Orga - Manufacturing site U-II received USFDA approvals. - Recommendation of Dividend @ 25% on Equity Shares i.e. Rs. 2.50 per share. 2012 - The Board of Directors has recommended a dividend of 30% on Equity Shares of Rs. 10/- each for the year. 2021 -The Company has issued Bonus Shares in the Ratio of 2:1. 2023-The Company's Flagship API site has been successfully inspected by Ministry of Food and Drug Safety, Republic of South Korea leading to the registration of product in the Korean market.
Read More
Parent Organisation
Smruthi Organics Ltd.
Founded
11/07/1989
Managing Director
Mr.Purushotham Eaga
NSE Symbol
FAQ
The current price of Smruthi Organics Ltd is
The 52-week high for Smruthi Organics Ltd is
The market capitalization of Smruthi Organics Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Smruthi Organics Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Smruthi Organics Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Smruthi Organics Ltd shares.
The CEO of Smruthi Organics Ltd is Mr.Purushotham Eaga, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
